[go: up one dir, main page]

CN111836807A - 氧杂螺环类化合物及其制备方法和用途 - Google Patents

氧杂螺环类化合物及其制备方法和用途 Download PDF

Info

Publication number
CN111836807A
CN111836807A CN201980016139.6A CN201980016139A CN111836807A CN 111836807 A CN111836807 A CN 111836807A CN 201980016139 A CN201980016139 A CN 201980016139A CN 111836807 A CN111836807 A CN 111836807A
Authority
CN
China
Prior art keywords
preparation
compounds
oxaspiro
application
oxaspiro compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980016139.6A
Other languages
English (en)
Inventor
田强
张毅涛
宋智泉
宋立强
蔡家强
王利春
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of CN111836807A publication Critical patent/CN111836807A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种氧杂螺环类化合物及其制备方法和用途，具体地，提供式(I)所示的化合物、其溶剂化物、立体异构体、晶型、药学可接受的盐或酯、或上述的任意组合，及其制备方法和在激活阿片样物质受体活性和用于制备镇痛药物中的用途，

Description

PCT国内申请，说明书已公开。

Claims (22)

  1. PCT国内申请，权利要求书已公开。
CN201980016139.6A 2018-04-28 2019-04-16 氧杂螺环类化合物及其制备方法和用途 Pending CN111836807A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810402312 2018-04-28
CN2018104023123 2018-04-28
CN2018113589173 2018-11-15
CN201811358917 2018-11-15
PCT/CN2019/082841 WO2019205983A1 (zh) 2018-04-28 2019-04-16 氧杂螺环类化合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
CN111836807A true CN111836807A (zh) 2020-10-27

Family

ID=68293799

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980016139.6A Pending CN111836807A (zh) 2018-04-28 2019-04-16 氧杂螺环类化合物及其制备方法和用途

Country Status (2)

Country Link
CN (1) CN111836807A (zh)
WO (1) WO2019205983A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112334465B (zh) * 2019-01-17 2024-06-11 上海海雁医药科技有限公司 三环取代的氧杂螺环衍生物、其制法与医药上的用途
CN111662284B (zh) * 2019-03-06 2021-08-10 上海海雁医药科技有限公司 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途
JP7481458B2 (ja) * 2020-01-17 2024-05-10 上海海雁医薬科技有限公司 光学的に純粋なオキサスピロ置換ピロロピラゾール誘導体、その調製方法及び医学的使用
EP4092031A4 (en) * 2020-01-17 2024-02-21 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Azabicyclic substituted oxaspiro derivative, preparation method therefor and medical use thereof
CN113214264B (zh) * 2020-01-21 2022-08-09 上海海雁医药科技有限公司 二氢吡咯并五元杂芳基取代的氧杂螺环衍生物、其制法与医药上的用途
CN112694485B (zh) * 2020-09-10 2023-04-07 四川海品信医药科技有限公司 一种阿片受体激动剂噻吩类化合物及其制备方法
EP4265604A4 (en) * 2020-12-29 2025-01-08 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. OXASPIRO-SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVE, INTERMEDIATE THEREOF, AND PREPARATION PROCESS THEREOF
WO2023284788A1 (zh) * 2021-07-13 2023-01-19 上海海雁医药科技有限公司 Mor受体激动剂的药学上可接受的盐、其多晶型物及其用途
MX2024001613A (es) * 2021-08-02 2024-02-27 Shujing Biopharma Co Ltd Derivado de oxaspiro, metodo de preparacion del mismo y uso del mismo.
CN117263956A (zh) * 2022-01-19 2023-12-22 天地恒一制药股份有限公司 阿片受体激动剂及其制备方法和用途
CN117126146A (zh) * 2022-05-25 2023-11-28 天地恒一制药股份有限公司 阿片受体激动剂及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103702561A (zh) * 2011-03-23 2014-04-02 特维娜有限公司 阿片样物质受体配体以及使用和制备其的方法
WO2017063509A1 (zh) * 2015-10-15 2017-04-20 江苏恒瑞医药股份有限公司 氧杂螺环类衍生物、其制备方法及其在医药上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11014914B2 (en) * 2017-04-14 2021-05-25 Jiangsu Hengrui Medicine Co., Ltd. Opioid receptor (MOR) agonist salt, fumarate salt crystal form I thereof and preparation method thereof
CN108727347B (zh) * 2017-04-14 2020-06-16 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
KR20190133047A (ko) * 2017-04-14 2019-11-29 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Mor 작용제 및 kor 작용제를 함유하는 약학적 조성물, 및 그의 용도
CN110678453B (zh) * 2017-09-28 2023-03-10 江苏恒瑞医药股份有限公司 一种氧杂螺环类衍生物的制备方法及其中间体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103702561A (zh) * 2011-03-23 2014-04-02 特维娜有限公司 阿片样物质受体配体以及使用和制备其的方法
WO2017063509A1 (zh) * 2015-10-15 2017-04-20 江苏恒瑞医药股份有限公司 氧杂螺环类衍生物、其制备方法及其在医药上的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN,XIAOTAO等: "Structure−Activity Relationships and Discovery of a G Protein Biasedμ Opioid Receptor Ligand, [(3-Methoxythiophen-2-yl)methyl]({2-[(9R)‑9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the Treatment of Acute Severe Pain" *
LI,XIN等: "Discovery of SHR9352: A Highly Potent G Protein-Biased μ‑Opioid Receptor Agonist" *

Also Published As

Publication number Publication date
WO2019205983A1 (zh) 2019-10-31

Similar Documents

Publication Publication Date Title
CN111836807A (zh) 氧杂螺环类化合物及其制备方法和用途
CN114222743A (zh) 氧代六元环并嘧啶类化合物，其制法与医药上的用途
CN115667238A (zh) 一种五并五元环衍生物及其在医药上的应用
CN114008035A (zh) 一种shp2磷酸酶变构抑制剂
CN109982699A (zh) 一种mor激动剂与kor激动剂的药物组合物及其用途
CN114269746A (zh) 一种螺芳环化合物、其制备及应用
CN114746413A (zh) 二氮杂吲哚类衍生物及其作为Chk1抑制剂的应用
CN113748114A (zh) 一种喹唑啉化合物及其在医药上的应用
JP2012502037A5 (zh)
JP2015155440A5 (zh)
JP2015083580A5 (zh)
JP2013509429A5 (zh)
JP2015516427A5 (zh)
CN113784963A (zh) 用作ret激酶抑制剂的化合物及其应用
JP2020097577A5 (zh)
JP2015523407A5 (zh)
JP2013542261A5 (zh)
CN109563060A (zh) Ido1抑制剂及其制备方法和应用
CN115667278A (zh) 乏氧活化的dna烷化剂及其医药用途
CN109689652A (zh) 稠杂环类衍生物、其制备方法及其在医学上的应用
JP2017517565A5 (zh)
CN111566100A (zh) 嘧啶类化合物、其制备方法及其医药用途
CN113166061A (zh) 含有磺酰基结构的RORγ抑制剂
CN114206850A (zh) 作为crac抑制剂的2h-苯并吡喃衍生物
CN111699174A (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201027

WD01 Invention patent application deemed withdrawn after publication